Ostepose Injection (Ibandronate Sodium Hydrate)
Ibandronate Sodium Monohydrate 3.375mg
Injections · Prescription medication
Hubist Pharma Co., Ltd.
MFDS item code 201801955 · Notified 2018.05.09
Treatment of osteoporosis in postmenopausal women
This medication is used for the treatment of osteoporosis in postmenopausal women.
Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible and continue regular dosing at 3-month intervals from then on. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or lower or whose creatinine clearance is 30ml/min or higher. Because clinical experience is insufficient in patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is below 30ml/min, use of this drug is not recommended. Older adults No dose adjustment is necessary.
Efficacy and safety in children 18 years of age and younger have not been studied.
This medication must be administered intravenously, and caution is required as administration into the artery or around the vein can cause tissue damage. It must not be used in patients with a history of allergic reactions to this drug or its components, or in patients with untreated hypocalcemia. Various side effects may occur, including gastritis, diarrhea, abdominal pain, indigestion, nausea, constipation, muscle pain, joint pain, headache, and rash. Some patients may experience flu-like symptoms such as fever, chills, fatigue, arthralgia, myalgia, which are generally transient and mild to moderate in severity. Osteonecrosis of the jaw may occur during treatment, so special caution is needed for cancer patients or those receiving dental treatments. Calcium and vitamin D intake must be sufficient before administration and during treatment; hypocalcemia or bone and mineral metabolism disorders must be adequately treated. Patients with poor renal function or taking medications that may affect the kidneys require regular check-ups and monitoring. During the administration of this drug, excessive dental treatment should be avoided, and oral hygiene should be well managed. This drug can rarely cause severe side effects such as ocular inflammation, severe allergic reactions, skin rashes, atypical fractures, so any unusual symptoms should be reported to medical staff immediately. Women who are pregnant or breastfeeding are advised not to use this drug, and safety and efficacy have not been established for children under 18 years of age. In cases of overdose, renal and liver damage may occur, necessitating careful monitoring and appropriate treatment. This drug should not be mixed with calcium-containing solutions or other intravenous medications and should be administered only as an intravenous injection. After use, the syringe and needle should not be reused and must be disposed of safely.
Gastritis, diarrhea, abdominal pain, indigestion, nausea, constipation, musculoskeletal pain, joint pain, muscle pain, influenza-like illness, fatigue, headache, rash, bone pain, weakness, injection site reaction, phlebitis, thrombophlebitis, hypersensitivity reaction, angioedema, facial swelling, edema, urticaria, osteonecrosis of the jaw and external auditory canal, uveitis, episcleritis, scleritis, anaphylactic reaction, shock, exacerbation of asthma, Stevens-Johnson syndrome, erythema multiforme, bullous dermatitis, atypical subtrochanteric and femoral diaphyseal fractures, atypical fractures of the ilium, dizziness, optic atrophy, lower motor neuron lesions, tremor, gastrointestinal disease unspecified, benign gastrointestinal neoplasm, toothache, hyperventilation, cough, dyspnea, laryngitis, vaginitis, menopausal symptoms, multiple organ failure, death, insomnia, anxiety, tinnitus, hearing loss, hypothyroidism, lipoma, ocular hemorrhage, heart failure, urination disorders, hematuria, skin desquamation, sensory loss, acute renal failure
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent exposure to air, and it is safe to store at a temperature between 1 and 30 degrees Celsius. Proper storage at the correct temperature can maintain the drug's efficacy and stability.
This injectable medication is a colorless, transparent solution contained in a colorless, transparent glass prefilled syringe with an attached single-use needle.
3ml x 1 vial
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Ibandronate Sodium Monohydrate 3.375mg
Injections · Prescription medication
Hubist Pharma Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Jeil Pharmaceutical Co., Ltd.
Ibandronate Sodium Monohydrate 3.375mg
Solution · Prescription medication
Jeil Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Chodang Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Ajou Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Aliko Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Teragen Etex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.